Changing what's possible for chronic respiratory disease
Developing disease-modifying respiratory immunotherapies
Respien is an Australian clinical-stage biotechnology company advancing novel therapies for chronic respiratory disease.
We are advancing a pipeline of innovative respiratory immunotherapies, led by HI-164, with the ambition of addressing significant unmet medical needs and improving long-term outcomes for people living with COPD and other chronic respiratory diseases.
Clinical-stage biotechnology
Developing novel immunotherapies to address the underlying drivers of chronic respiratory disease.
Lead program: HI-164
Progressing a Phase 3-ready program towards late-stage clinical development.
Growing pipeline
Building the next generation of therapies to broaden our impact across respiratory care.
Partnering opportunities
Seeking strategic collaborations to accelerate development and deliver innovative therapies to patients worldwide.
We believe the future of respiratory medicine lies in targeting the biological drivers of disease
Our research is focused on the biological pathways that drive chronic respiratory disease, with the goal of developing therapies that modify disease progression rather than managing symptoms alone.
Every innovation we pursue is driven by one ambition: helping people breathe well, spend less time managing their condition and more time living healthier, fuller lives.
COPD: A persistent global health challenge
Despite advances in respiratory medicine, COPD remains one of the world's leading causes of death. Recurrent bacterial respiratory exacerbations continue to drive hospitalisations, healthcare costs and declining patient health—highlighting the need for therapies that move beyond symptom management.
Every exacerbation can accelerate disease progression, reduce quality of life and take people further from the moments that matter.
COPD places a growing burden on patients, healthcare systems and economies worldwide.
Introducing our lead clinical asset: HI-164
HI-164 is Respien's Phase 3-ready lead asset, developed from our proprietary oral immunotherapy platform. Designed to target the biological drivers of bacterial respiratory exacerbations, it represents a differentiated disease-modifying approach with the potential to reduce exacerbations, improve quality of life and complement existing standards of care.
Reduced hospital admissions
Clinical studies demonstrated reductions in hospital admissions of up to 73%, helping people spend less time in hospital and more time living well.
Up to 73% fewer COPD hospital admissions
Up to 69% fewer all-cause hospital admissions
Demonstrated across two Phase II clinical studies
Patients studied
HI-164 has been evaluated in more than 500 patients across multiple clinical studies, providing a robust body of evidence to support its continued development.
Two completed Phase II clinical trials
Double-blind, randomised, placebo-controlled studies
Patients treated alongside standard of care
Clinically significant improvement
Clinical studies demonstrated significant improvements in SGRQoL symptom scores just 12 weeks after starting treatment in patients under 65 years of age.
Significant improvement at 12 weeks (P=0.02)
Sustained benefit at 24 weeks (P=0.01)
Improved SGRQ quality of life symptom scores
Clinical development
More than a decade of research and clinical development has shaped HI-164, building a strong scientific foundation and a differentiated oral immunotherapy platform.
Developed through more than a decade of respiratory research
Targeting bacterial respiratory exacerbations in COPD
Progressing towards global late-stage development
Building a pipeline for the future of chronic respiratory disease.
HI-164 - Lead programme
✓ Phase 3-ready
✓ COPD & NCFB
✓ Priority review candidate
TA-270 - Next-generation programme
✓ Inhaled anti-inflammatory
✓ COPD & NCFB
✓ Oral dosing confirms biological effects
ANON - Future programme
✓ Inhaled anti-inflammatory
✓ COPD & NCFB
✓ Non-antibiotic anti-infective, to treat resistant microbial infections
